– SWITZERLAND, Neuchatel – Aktiia, the hypertension health-tech firm today announced a $17.5M Series A funding round led by Draper Esprit alongside 415 CAPITAL, Redalpine Venture Partners, Verve Capital, and Translink Capital also participating in the round.
Aktiia already has tens of thousands of consumers across the UK, Ireland, Germany, Austria, France, Switzerland, and Italy. This Series A will be used to expand its offer to healthcare systems within these geographies as well as move into new territories.
“At Aktiia, we believe the key to improving cardiovascular health is to provide patients and physicians a deeper understanding of their blood pressure pattern,” said CEO, Mike Kisch. “Before Aktiia, it was not possible to do this at scale. We are excited about expanding access to this technology and the positive impact it can have on reducing major adverse cardiovascular events.”
Aktiia’s revolutionary 24-7 automated blood pressure monitoring system enables stress-free reading round the clock and has the potential to transform the diagnosis and treatment of hypertension, which affects approximately 1.28 billion adults worldwide and is a leading cause of premature death.
In addition to endorsement by leading clinicians in hypertension management, Aktiia is now also an official partner of the International Society of Hypertension.
Since its launch in Spring 2021, Aktiia now has tens of thousands of users, who on average check their blood pressure data over sixteen times a week, with an average of 150 weekly readings performed by the device automatically in the background. The data is then visualized in a free companion application; with a simple click, a digital summary can be easily shared with a physician or family member. In contrast, the average hypertensive patient currently measures their blood pressure only once per week due to the inconvenience and discomfort associated with a traditional cuff. Combined with white coat hypertension, masked hypertension, and other common issues with in-office diagnosis, this sporadic at-home monitoring can lead to poor management and delays in optimizing treatment.
About Aktiia
Founded in Switzerland in May 2018, Aktiia’s team has some of the world’s leading scientific and technical experts in optical blood pressure monitoring, including CTO, Dr. Josep Sola, a pioneer in cuffless blood pressure monitoring and editor of “The Handbook of Cuffless Blood Pressure Monitoring.” The core technology was first developed over decades of research at the prestigious Swiss Center for Electronics and Microtechnology (CSEM), under a team led by Aktiia co-founders, Dr. Mattia Bertschi and Dr. Josep Sola.
For more, visit Aktiia.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
